Jaguar Health, Inc.
Close on Oct 19, 2026
- Market cap
- $2.28M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 19, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 20, 2026 | After market close | $20.27M | $-13.60 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | Before market open | $3.50M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | Before market open | $3.10M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | Before market open | $2.72M | $-4.04 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 14, 2023 | Before market open | $2.68M | $-0.42 | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 15, 2023 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 27, 2023 | Before market open | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 14, 2022 | Before market open | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 10, 2022 | Before market open | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 11, 2022 | After market close | – | – | – |
Press releases
Announcements Jaguar Health filed with the SEC
Jaguar Health Announces a Special Stock Dividend
Material agreement · New financial obligation · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
otherwise requires, references herein to “Jaguar,” the “Company,” “we,” “us,” and “our” refer to Jaguar Health, Inc. Terms used but not defined herein have the respective meanings set forth
Material agreement · New financial obligation · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Jaguar Health, Inc. Announces Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Jaguar Health Reports Second Quarter 2026 Financials
Results of operations · EX-99.1 to Form 8-K
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
Material agreement · Other events · EX-99.1 to Form 8-K
Jaguar Health Announces Plan to Explore Strategic Alternatives
Regulation FD disclosure · EX-99.1 to Form 8-K/A
Jaguar Health Announces Plan to Explore Strategic Alternatives to Align with Targeted NDA for Rare
Regulation FD disclosure · EX-99.1 to Form 8-K
Jaguar Health Reports Approval of All Proposals at 2026
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Jaguar Health Compliant with Nasdaq Bid Price Rule
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Jaguar Health Reports First Quarter 2026 Financials
Results of operations · EX-99.1 to Form 8-K
Jaguar Health Granted Extension Until May 15, 2026, to
Listing notice · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders
Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Jaguar Health Reports 2025 Financials
Results of operations · EX-99.1 to Form 8-K
Jaguar Health Announces a Special One-time Stock Dividend
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
otherwise requires, references herein to “Jaguar,” the “Company,” “we,” “us,” and “our” refer to Jaguar Health, Inc. Terms used but not defined herein have the respective meanings set
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Jaguar Health Reports First Quarter 2025 Financials
Material agreement · Results of operations · New financial obligation · Unregistered share sale · Charter or bylaw amendment · EX-99.1 to Form 8-K
Jaguar Health, Inc. (NASDAQ: JAGX)
Regulation FD disclosure · EX-99.1 to Form 8-K
Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5%
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Jaguar Health, Inc. (NASDAQ: JAGX) Overview – April 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Jaguar Health, Inc. (NASDAQ: JAGX) Overview – April 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023
Results of operations · EX-99.1 to Form 8-K
Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Jaguar Health, Inc. Announces Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value
Material agreement · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Jaguar Health Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Jaguar Health Reports Phase 3 OnTarget Trial
Regulation FD disclosure · EX-99.1 to Form 8-K
Regains Compliance with Nasdaq’s Bid Price Requirement
Other events · EX-99.1 to Form 8-K
Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Jaguar Health, Inc. Announces Reverse Stock
Material agreement · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
Shareholder vote results · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
GEN to Commercialize Jaguar Health’s Crofelemer
Unregistered share sale · Other events · EX-99.1 to Form 8-K